Regeneron/$REGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ticker
$REGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
15,158
ISIN
US75886F1075
Website
Regeneron Metrics
BasicAdvanced
$57B
13.76
$39.43
0.43
$1.76
0.65%
Price and volume
Market cap
$57B
Beta
0.43
52-week high
$1,206.81
52-week low
$476.49
Average daily volume
1.1M
Dividend rate
$1.76
Financial strength
Current ratio
4.927
Quick ratio
5.017
Long term debt to equity
9.204
Total debt to equity
9.204
Dividend payout ratio (TTM)
2.08%
Interest coverage (TTM)
82.68%
Profitability
EBITDA (TTM)
4,448
Gross margin (TTM)
48.77%
Net profit margin (TTM)
31.94%
Operating margin (TTM)
28.06%
Effective tax rate (TTM)
9.73%
Revenue per employee (TTM)
$930,000
Management effectiveness
Return on assets (TTM)
6.87%
Return on equity (TTM)
15.96%
Valuation
Price to earnings (TTM)
13.76
Price to revenue (TTM)
4.145
Price to book
1.96
Price to tangible book (TTM)
2.04
Price to free cash flow (TTM)
19.714
Free cash flow yield (TTM)
5.07%
Free cash flow per share (TTM)
2,751.96%
Dividend yield (TTM)
0.32%
Forward dividend yield
0.65%
Growth
Revenue change (TTM)
7.52%
Earnings per share change (TTM)
16.49%
3-year revenue growth (CAGR)
-5.15%
10-year revenue growth (CAGR)
16.48%
3-year earnings per share growth (CAGR)
-17.53%
10-year earnings per share growth (CAGR)
29.26%
What the Analysts think about Regeneron
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Bulls say / Bears say
Regeneron's experimental weight-loss drug, trevogrumab, combined with Novo Nordisk's semaglutide, demonstrated positive outcomes in a mid-stage study, helping patients preserve up to 80% of their lean muscle mass while increasing fat loss. (reuters.com)
The company secured a significant legal victory against Amgen, with a federal jury awarding Regeneron over $406 million for anticompetitive practices related to the cholesterol-lowering drug market. (reuters.com)
Regeneron announced a 10-year agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supply its commercial bulk drug product, nearly doubling the company's large-scale manufacturing capacity in the United States. (stocktitan.net)
Regeneron is facing a securities fraud class action lawsuit after its stock price plunged $84.59 on October 31, 2024, erasing approximately $9 billion from the company's market capitalization. (tradingview.com)
Analysts have lowered their price targets for Regeneron due to concerns over sales figures and ongoing legal challenges, with TD Cowen reducing its target to $1,030 from $1,230. (abc27.com)
Regeneron's stock experienced a significant decline in September 2024 following a legal setback that opened the door for an early launch of a competing therapy to its blockbuster eye treatment, Eylea. (bloomberg.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Jun 2025.
Regeneron Financial Performance
Revenues and expenses
Regeneron Earnings Performance
Company profitability
Regeneron News
AllArticlesVideos
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
WSJ·3 weeks ago
US FDA approves Regeneron's blood cancer therapy
Reuters·3 weeks ago
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $57B as of July 21, 2025.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 13.76 as of July 21, 2025.
Does Regeneron stock pay dividends?
Yes, the Regeneron (REGN) stock pays dividends to shareholders. As of July 21, 2025, the dividend rate is $1.76 and the yield is 0.65%. Regeneron has a payout ratio of 2.08% on a trailing twelve-month basis.
When is the next Regeneron dividend payment date?
The next Regeneron (REGN) dividend payment date is unconfirmed.
What is the beta indicator for Regeneron?
Regeneron (REGN) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.